|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1600 - 0.1600|
|52 Week Range||0.1500 - 0.9550|
|Beta (3Y Monthly)||3.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 15, 2019 - Jul 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that its Board of Directors has appointed Nancy R. Phelan to serve as Chief Executive Officer of the Company. Ms. Phelan has served as a member of the Board of Directors since October 2018. “I am excited to assume the role of Chief Executive Officer of Adhera Therapeutics,” Ms. Phelan said.
Over 200 prescribers have written at least one prescription for PRESTALIA and over 600 patients are taking the medication PRESTALIA was launched in Q3 2018, powered by the Company's proprietary DyrctAxess ...
Research Triangle Park, NC, Nov. 20, 2018 -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its.
Innovative Technology enables the pharmaceutical industry to transition to an orchestrated commercial model